- $100.33bn
- $119.79bn
- £32.67bn
UK Stocks-Factors to watch on September 3
HUTCHMED (China) signs exclusive licensing deal with GSK for investigational cancer drug
Brief: Hutchmed Announces Licensing Agreement With GSK For Kras-Egfr-Antibody Conjugate Cancer Therapy
UK Stocks-Factors to watch on September 1 (updated)
Brief: GSK's mRNA flu vaccine moves into Phase III testing
Corrected: UPDATE 1-GSK to advance mRNA flu vaccine to late-stage trial
GSK to advance mRNA flu vaccine to late-stage trial
mRNA flu vaccine candidate to advance to phase III
Director/PDMR Shareholding
Brief: US FDA Approves Drug To Treat HIV Infection In Newborns
Director/PDMR Shareholding
GSK scores regulatory wins for chronic hepatitis B drug, cancer therapy
Brief: GSK Receives First Global Approval For Hibsago In Japan
Brief: GSK Says US FDA To Review Jemperli For Rectal Cancer
First global approval for Hibsago in Japan
US FDA to review Jemperli for rectal cancer
Director/PDMR Shareholding
Brief: GSK Says Nucala Receives Positive Reimbursement Recommendation From CDA-AMC
Sandoz to license three biosimilar drugs from Shanghai Henlius Biotech (updated)